Kabushiki Kaisha Yakult Honsha

Keio University

Gunma University

Hiroyuki Takahashi

Shinji Sugimoto

Yusuke Tanigawara

Akito Nishimuta

Junya Tsuzaki

Masahiko Nishiyama

Susumu Rokudai

Shinji Yoshiyama

Miki Tanaka

Kanako Hara

Provided is a method for efficiently manufacturing high-purity peripheral nerve cells from undifferentiated cells. The method for manufacturing peripheral nerve cells from undifferentiated cells having an ability to differentiate into peripheral nerve cells includes the following steps (a) and (b): (a) culturing undifferentiated cells having an ability to differentiate into peripheral nerve cells to induce differentiation into neural progenitor cells without detaching a grown colony from a culture vessel; and (b) detaching the neural progenitor cells produced in the step (a) from the culture vessel, then seeding the cells at a seeding density of 2&#xd7;10to 6&#xd7;10cells/cmto a culture vessel, and culturing the cells for 14 to 42 days.

Method for manufacturing peripheral nerve cells

To provide an anti-cancer agent sensitivity determination marker, which marker can determine whether or not the patient has a therapeutic response to the anti-cancer agent, and novel cancer therapeutic means employing the marker. The anti-cancer agent sensitivity determination marker, the anti-cancer agent including oxaliplatin or a salt thereof and fluorouracil or a salt thereof, contains one or more substances selected from among an amino-acid-metabolism-related substance, a nucleic-acid-metabolism-related substance, a substance in the pentose phosphate pathway, a substance in the glycolytic pathway, a substance in the TCA cycle, a polyamine-metabolism-related substance, 7,8-dihydrobiopterin, 6-phosphogluconic acid, butyric acid, triethanolamine, 1-methylnicotinamide, NADH, NAD, and a substance involved in the metabolism of any of these substances.

Combined anticancer drug sensitivity-determining marker

Growing community of inventors

Minato-ku, Japan

Hiroyuki Takahashi